FHI Clinical and Oracle bring critical clinical trial capabilities to markets in need

October 12, 2020

Study sponsors and global health organizations can take advantage of Oracle Health Sciences Clinical One cloud platform to improve clinical trial efficiency

Oracle Health Sciences and FHI Clinical Inc., a contract research organization (CRO) that manages complex research in resource-limited settings around the world, have joined efforts to improve clinical trial efficiency and help get therapies to market faster.

From Ebola to coronavirus, responses to outbreaks require diligent, coordinated approaches to be effective. Clinical trials must be established quickly; however, in regions without existing research capacity, study start-up through the entire study lifecycle can be challenged by a lack of regulatory guidance, infrastructure, qualified staff, established sites, and laboratory facilities.

Oracle Health Sciences Clinical One is the only cloud platform built from the ground-up to support all the core capabilities required for effective study management throughout the entire drug development lifecycle. With the ability to capture data from any source into a single, unified platform, Clinical One is redefining how technology supports clinical research to improve efficiency and help speed the delivery of breakthrough therapies.

“Based on our experience in crisis-response settings, the FHI Clinical team has developed a systematic approach to rapid study start-up that can be used across geographies and therapeutic areas,” said Ted FitzGerald, FHI Clinical president and CEO. “Integrating the Oracle Clinical One platform into our approach allows us to bring best-in-class clinical software to markets and segments previously neglected, enabling us to meet compressed trial timelines with the highest quality data possible. As trial needs evolve and change, we are equipping our clients both large and small to be prepared for those changes with the ease and flexibility of Clinical One.”

FHI Clinical has adopted Oracle Health Sciences Clinical One for randomization, supply management, and data collection. The company also uses Oracle Argus Safety for safety case management; Oracle Clinical Trial Management System (CTMS) Cloud Service to manage the entire research portfolio, including study status and financial reporting; and Oracle ClearTrial Cloud Service to help budget, plan and bid on projects.

“With Oracle, FHI Clinical can position its clients for the future of clinical trials, which are evolving as the industry grows and adapts,” said Henry McNamara, senior vice president and general manager, Oracle Health Sciences. “Clinical One is like no other platform on the market – truly unifying people, processes, and data in a way that’s never been done before. We are honored to help FHI Clinical bring our Clinical One innovation to organizations that have traditionally had limited access to the technology needed to solve these important global healthcare priorities.”

Related news:

news archive

Evaluation of baricitinib versus dexamethasone for adults hospitalized with COVID-19 in the global ACTT-4 study

September 7, 2022
The global ACTT-4 study, supported by FHI Clinical, evaluated baricitinib vs dexamethasone for adults hospitalized with COVID-19. This trial is the fourth and final stage in a series of phase 3, randomized, double-blind, placebo-controlled trials to evaluate the clinical efficacy and safety of investigational therapeutic agents in hospitalized adults with laboratory-confirmed COVID-19.

Read more »

FHI Clinical announces the closing of its acquisition of the clinical trials business of South Africa-based Triclinium Clinical Development (TCD)

February 8, 2022
FHI Clinical Inc. announces today the official closing of its acquisition of the clinical trials business of Triclinium Clinical Development Proprietary Limited (TCD), a full-service, South Africa-based CRO. With the acquisition, FHI Clinical expands its share of the infectious disease (ID) clinical development market and becomes the dominant service provider in sub-Saharan Africa.

Read more »